Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931013 | 0.89 | RAB9A (0.41) | THRBMAPTRORCTP53RAB9A | |
| SCHEMBL13930752 | 0.89 | RAB9A (0.41) | THRBMAPTRORCTP53RAB9A | |
| SCHEMBL13930735 | 0.77 | OPRM1 (0.47) | THRBMAPTTP53RAB9APOLB | |
| SCHEMBL13930847 | 0.77 | OPRM1 (0.47) | THRBMAPTTP53RAB9APOLB | |
| SCHEMBL13931017 | 0.76 | FUCA1 (0.45) | TP53RAB9APOLBALDH1A1CHRM2 | |
| SCHEMBL13952151 | 0.76 | FUCA1 (0.45) | TP53RAB9APOLBALDH1A1CHRM2 | |
| SCHEMBL13930709 | 0.76 | MAPT (0.42) | MAPTRORCTP53RAB9ASMN1; SMN2 | |
| SCHEMBL13930683 | 0.72 | KCNJ6 (0.41) | MAPTSMN1; SMN2TSHR | |
| SCHEMBL13930731 | 0.71 | EPHX2 (0.44) | MAPTRAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13930679 | 0.71 | OPRM1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | THRB 3487/4885MAPT 2479/4885RORC 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.